Document Detail

[In Process Citation].
MedLine Citation:
PMID:  23535546     Owner:  NLM     Status:  In-Data-Review    
Screening for malignant disease aims to reduce the population risk of impaired health due to the tumor in question. Screening does not only entail testing but covers all steps required to achieve the intended reduction in risk, from the appropriate information of the population to a suitable therapy. Screening tests are performed in individuals free or unaware of any symptoms associated with the tumor. An essential condition is a recognizable pathological abnormality, which occurs without symptoms and represents a pre-clinical, early stage of the tumor. Overdiagnosis and overtreatment have only recently been recognized as important problems of screening for malignant disease. Overdiagnosis is defined as a screening-detected tumor that would never have led to symptoms. In prostate-specific antigen (PSA) screening for prostate cancer 50 % - 70 % of screening-detected cancers represent such overdiagnoses. Similarly, in the case of mammography screening 20 % - 30 % of screening-detected breast cancers are overdiagnoses. The evaluation of screening interventions is often affected by biases such as healthy screenee effects or length and lead time bias. Randomized controlled trials are therefore needed to examine the efficacy and effectiveness of screening interventions and to define the rate of adverse outcomes such as unnecessary diagnostic evaluations, overdiagnosis and overtreatment. Unfortunately there is no independent Swiss body comparable to the National Screening Committee in the United Kingdom or the United States Preventive Services Task Force, which examines screening tests and programs and develops recommendations. Clearly defined goals, a central organization responsible for inviting eligible individuals, documentation and quality assurance and balanced information of the public are important attributes of successful screening programs. In Switzerland the establishment of such programs is hampered by the highly fragmented, Federal health system which allows patients to access specialists directly.
Matthias Egger; Marcel Zwahlen; Thomas Cerny
Publication Detail:
Type:  English Abstract; Journal Article    
Journal Detail:
Title:  Therapeutische Umschau. Revue thérapeutique     Volume:  70     ISSN:  0040-5930     ISO Abbreviation:  Ther Umsch     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-03-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0407224     Medline TA:  Ther Umsch     Country:  Switzerland    
Other Details:
Languages:  ger     Pagination:  195-203     Citation Subset:  IM    
Institut für Sozial- und Präventivmedizin, Universität Bern.
Vernacular Title:
Tumorscreening - Grundlagen, Evaluation und Implementation.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Protective efficacy of orally administered, heat-killed Lactobacillus pentosus b240 against influenz...
Next Document:  [In Process Citation].